Last reviewed: June 4, 2026
Last updated: June 4, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Semaglutide (Wegovy) and tirzepatide (Mounjaro) are often mentioned together in weight loss conversations, yet they work through fundamentally different biological pathways. Semaglutide activates one hormone receptor (GLP-1), while tirzepatide activates two (GLP-1 and GIP), which explains their varying effectiveness across different patient populations. Choosing between them depends on your individual metabolism, health history, and weight loss goals.
How GLP-1 Agonists Like Wegovy Support Weight Loss
Semaglutide, the active ingredient in Wegovy, mimics glucagon-like peptide-1, a hormone your gut naturally produces after eating. When GLP-1 receptors in your brain's appetite center receive this signal, hunger diminishes and feelings of fullness arrive faster. This mechanism slows gastric emptying, meaning food stays in your stomach longer, which further extends satiety between meals.
Clinical trials demonstrate that GLP-1 monotherapy produces meaningful weight reduction in most patients. The STEP trials showed average weight losses ranging from 15% to 22% of starting body weight over 68 weeks with semaglutide treatment. Beyond appetite control, semaglutide improves insulin sensitivity and helps regulate blood sugar levels, making it particularly valuable for individuals with prediabetes or type 2 diabetes.
Understanding Dual-Action GIP/GLP-1 Agonists and Tirzepatide
Tirzepatide activates both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors simultaneously. GIP is another gut hormone that influences blood sugar regulation, energy expenditure, and appetite. By engaging both pathways, tirzepatide creates a dual-hormone signal that addresses weight management through multiple biological mechanisms at once.
The SURMOUNT trials comparing tirzepatide to semaglutide revealed that dual agonism produces greater average weight loss, with participants losing up to 22.5% of body weight at the highest dose. Tirzepatide also demonstrated superior improvements in cardiovascular risk markers and glucose control. However, this enhanced efficacy sometimes comes with a higher rate of gastrointestinal side effects during initial dose escalation.
Comparing Clinical Outcomes: Head-to-Head Evidence
When directly compared in clinical research, tirzepatide consistently outperforms semaglutide for weight reduction, particularly in participants with obesity and metabolic dysfunction. In the SURMOUNT-7 trial, tirzepatide 10 mg weekly produced approximately 21% weight loss versus approximately 16% with semaglutide 2.4 mg weekly. These differences become more pronounced in individuals with insulin resistance or prediabetes, where the GIP pathway activation offers additional metabolic benefit.
Response variability matters significantly—some patients achieve their goals equally well with either medication, while others show dramatically different results. Genetic factors influencing peptide receptor sensitivity, such as variations in the GLP1R and GIPR genes, help explain why one person thrives on semaglutide while another needs tirzepatide's dual action. PlexusDx Precision Peptide Genetic Test identifies your genetic predisposition across 14 metabolic pathways, revealing which compounds align best with your biology.
Side Effects, Tolerability, and Individual Suitability
Semaglutide side effects are typically mild to moderate and include nausea, vomiting, constipation, and occasional diarrhea, most pronounced during dose escalation. Many patients experience symptom improvement within two to four weeks as their body adapts. The gastrointestinal tolerability profile makes semaglutide an attractive choice for individuals sensitive to medication side effects or those with a history of pancreatitis.
Tirzepatide's dual-receptor activation can produce more pronounced early gastrointestinal symptoms in some patients due to stronger signaling through multiple pathways. Starting at a low dose and titrating gradually minimizes these effects for most individuals. Despite higher initial side effect rates in trials, tirzepatide discontinuation due to adverse events remains low, suggesting that most patients adapt successfully. Your personal risk factors, medication history, and digestive sensitivity should guide selection between these options.
Cost, Access, and Personalized Treatment at PlexusDx
PlexusDx offers compounded tirzepatide injection starting at $249 per month through licensed 503A compounding pharmacies, with no insurance requirement and no membership fees. This pricing structure—flat-rate regardless of dose escalation—ensures your costs remain predictable as your physician adjusts your therapeutic dose. HSA and FSA accounts cover PlexusDx medications, making treatment accessible across various insurance and financial situations.
PlexusDx also provides compounded semaglutide injection starting at $149 per month for patients who prefer single-pathway therapy or require more gradual treatment initiation. Adding PlexusDx Precision Peptide Genetic Test ($99) after your first treatment month reveals your genetic predisposition across key weight-regulating genes (GLP1R, GIPR, FTO, MC4R), helping your clinician optimize your compound selection and dosing strategy. All medications come from licensed 503A compounding pharmacies across all 50 states.
Which Option Matches Your Weight Loss Goals?
Semaglutide (compounded or brand-name Wegovy) suits patients seeking a well-established, single-pathway therapy with excellent tolerability, those with mild to moderate weight loss needs, and individuals who prefer gentler initial side effects. It remains highly effective for sustainable, long-term weight management when combined with lifestyle modifications.
Tirzepatide appeals to patients with significant weight loss goals (25% or more), those with concurrent metabolic dysfunction like prediabetes or elevated triglycerides, and individuals who tolerate mild gastrointestinal effects in exchange for superior outcomes. PlexusDx compounded tirzepatide injection delivers dual-hormone efficacy at a fraction of brand-name prices, starting at $249 monthly. Working with a PlexusDx clinician and exploring genetic testing helps you select the compound—semaglutide, tirzepatide, or even a dual oral formula—that aligns with your unique metabolic profile and treatment philosophy.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Is Wegovy more effective than Mounjaro, or vice versa?
Clinical trials show tirzepatide (Mounjaro) produces greater average weight loss than semaglutide (Wegovy), particularly in people with insulin resistance. However, individual response varies significantly based on genetics and lifestyle.
Can I switch from Wegovy to Mounjaro if I'm not seeing results?
Yes, switching medications is a standard clinical strategy if your weight loss plateaus or stalls. Your PlexusDx clinician can transition you from compounded semaglutide to tirzepatide-based treatment, often beginning at a low dose. Many patients who didn't reach their goals on monotherapy respond well to dual-pathway activation with tirzepatide.
What is the cost difference between Wegovy and Mounjaro at PlexusDx?
PlexusDx compounded semaglutide injection starts at $149 per month, while compounded tirzepatide injection starts at $249 per month. Both maintain flat pricing regardless of dose escalation, so your cost remains stable as your clinician optimizes your treatment. No insurance is required, and both are HSA/FSA eligible.
Which medication causes fewer side effects?
Semaglutide typically produces milder initial gastrointestinal side effects than tirzepatide, making it easier to tolerate during dose escalation. Tirzepatide's dual-pathway activation can cause stronger early nausea or vomiting in some patients, though most adapt within two to four weeks.
How does PlexusDx Precision Peptide Genetic Test help me choose between these medications?
The test analyzes your genetics across 14 metabolic pathways, including GLP1R and GIPR variants that influence how your body responds to each compound. Variants in these genes predict whether you'll respond robustly to single-pathway (semaglutide) or dual-pathway (tirzepatide) therapy.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Do GLP-1 Lower Cholesterol? Insights into Heart Health Benefits
Optimizing Your Tirzepatide Shot Schedule for Effective Weight Management